CellVoyant, a Bristol, UK-based AI-first biotechnology spin-out from the University of Bristol accelerating the development of new stem cell therapies, raised £7.6M in Seed funding.

CellVoyant是英国布里斯托尔大学（University of Bristol）推出的第一个人工智能生物技术衍生产品，加速了新干细胞疗法的开发，筹集了760万英镑的种子资金。

The round was led by Octopus Ventures, with participation from Horizons Ventures, Verve Ventures, and Air Street Capital.

这一轮由Octopus Ventures牵头，来自Horizons Ventures、Verve Ventures和Air Street Capital。

The company intends to use the funds to scale the business, including doubling the team size over the next two years, expanding laboratory and experimental infrastructure, and advancing AI capabilities.

该公司打算利用这些资金扩大业务规模，包括在未来两年将团队规模扩大一倍，扩大实验室和实验基础设施，以及提高人工智能能力。

Led by Professor Rafael Carazo Salas, Founder and CEO, CellVoyant is an AI-first biotechnology company creating novel stem cell-based therapies for chronic diseases. Its technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale.

CellVoyant由创始人兼首席执行官拉斐尔·卡拉佐·萨拉斯教授领导，是人工智能领域首家创建新型干细胞治疗慢性病的生物技术公司。它的技术使用人工智能第一活细胞成像来预测和优化干细胞分化，以大规模可控地制造体内任何细胞和组织。

.

.

FinSMEs

FinSME

26/02/2024

26/02/2024